Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?

1 hour ago 2

Reuben Gregg Brewer, The Motley Fool

Sat, June 20, 2026 astatine 11:35 AM CDT 4 min read

Novo Nordisk (NYSE: NVO) kicked disconnected a revolutionary displacement successful however obesity is treated. The goal, astatine first, was to assistance diabetics woody with value loss, but the accidental to grow beyond that 1 unwellness has proven adjacent much attractive. The biggest caller improvement is Novo Nordisk's instauration of a Wegovy pill, which has been precise good received. Here's what you request to see arsenic you measure Novo Nordisk and the broader GLP-1 space.

There are lone 2 notable GLP-1 players close present

Novo Nordisk's Wegovy changeable was the archetypal GLP-1 cause connected the scene. There was truthful overmuch request that the institution couldn't nutrient capable of the medication. That was a large occupation for the institution due to the fact that it opened the doorway to lower-cost generic versions successful the U.S. market. And erstwhile rival Eli Lilly (NYSE: LLY) introduced its ain GLP-1 drugs (Mounjaro and Zepbound) that were much effective, Novo Nordisk rapidly recovered itself trailing successful the marketplace it had efficaciously created.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

A portion measurement with a heap of pills.

That said, consumers don't truly similar taking injections. So a 2nd contention was taking signifier betwixt these 2 pharmaceutical giants. Once again, Novo Nordisk was archetypal to market, this clip with a pill mentation of Wegovy. It is precise popular, having rapidly reached 3 cardinal prescriptions. Its maturation has been adjacent faster than that of the Wegovy shot, which makes logical sense. Consumers already cognize and spot Wegovy, truthful taking it successful a pill signifier is simply a reasonably casual step.

What's absorbing is that Eli Lilly has besides launched a GLP-1 pill. The pill is Foundayo, which is simply a antithetic cause from Mounjaro and Zepbound. Not lone does it look to beryllium little effectual than the Wegovy pill, but arsenic a caller drug, it has a harder way arsenic it needs to beryllium introduced to consumers. This gives Novo Nordisk a large opening to summation marketplace stock successful the GLP-1 niche.

Novo Nordisk is successful a modulation twelvemonth

Wall Street has seemingly abandoned Novo Nordisk, with the banal down 70% from its 2024 highs adjacent arsenic Eli Lilly trades adjacent its all-time highs. And determination appears to beryllium a bully crushed for interest implicit the abbreviated term, arsenic Novo Nordisk has warned that 2026 volition beryllium a hard year. The large communicative is pricing: the institution has agreed to little cause costs successful the U.S. marketplace and is facing generic contention successful India.

Read Entire Article